Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cost-effectiveness and clinical effectiveness of subcutaneous immunotherapy for allergic rhinitis
NL-OMON37299Recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of alutard-sq in allergic rhinitis (AR) (2 arms), sponsored by Erasmus MC. Primary endpoints: Cost per successfully treated patient, Mean daily total rhinitis symptom score and 2 more. Started Sep 2009; status: recruiting.
02
Drugs
alutard-sq
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NL-OMON37299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37299.